166 results found.

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using insulin degludec; insulin glargine

Novo Nordisk - Recruiting 18 years or older.
- A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2).
insulin degludec; insulin glargine

Type 2 Diabetes Clinical Trial using MK-3102; Sitagliptin; Placebo to MK-3102; Placebo to Sitagliptin; Open-label Metformin; Open-label Glimepiride

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin.
MK-3102; Sitagliptin; Placebo to MK-3102; Placebo to Sitagliptin; Open-label Metformin; Open-label Glimepiride

Type 2 Diabetes Mellitus Clinical Trial using MK-3102; Placebo

Merck Sharp & Dohme Corp. - Recruiting 40 years or older.
- A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Subjects With Type 2 Diabetes Mellitus.
MK-3102; Placebo

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using insulin degludec; insulin glargine

Novo Nordisk - Recruiting 50 years or older.
- A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events.
insulin degludec; insulin glargine

Diabetes Mellitus, Type 2 Clinical Trial using Trazenta

Boehringer Ingelheim - Recruiting N/A or older.
- Post Marketing Surveillance on Long Term Drug Use of Trazentar Tablets as add-on Therapy in Patients With Type 2 Diabetes Mellitus.
Trazenta

Type 2 Diabetes Mellitus Clinical Trial using Exenatide Once Weekly; Placebo

Bristol-Myers Squibb - Recruiting 18 years or older.
- Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus..
Exenatide Once Weekly; Placebo

Diabetes Mellitus, Type 2 Clinical Trial using Canagliflozin 100 mg; Canagliflozin 50 mg; Canagliflozin 300 mg; Placebo

Janssen Research & Development, LLC - Recruiting 10 years to 17 years.
- Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ò10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin.
Canagliflozin 100 mg; Canagliflozin 50 mg; Canagliflozin 300 mg; Placebo

Type 2 Diabetes Mellitus Clinical Trial using MK-3102; Matching placebo to MK-3012; Glimepiride; Metformin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin.
MK-3102; Matching placebo to MK-3012; Glimepiride; Metformin

Type 2 Diabetes Mellitus Clinical Trial using Ertugliflozin (5 mg); Ertugliflozin (10 mg); Placebo to Ertuglifozin; Metformin; Placebo to Metformin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-blind, Placebo-controlled, 26-week Multicenter Study With a 26-Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise.
Ertugliflozin (5 mg); Ertugliflozin (10 mg); Placebo to Ertuglifozin; Metformin; Placebo to Metformin

Type 2 Diabetes Mellitus Clinical Trial using MK-3102; Placebo to MK-3102; Glipizide; Placebo to glipizide; Insulin

Merck Sharp & Dohme Corp. - Recruiting 30 years or older.
- A Phase III, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MK-3102 Versus Placebo in Subjects With Type 2 Diabetes Mellitus With Moderate or Severe Chronic Kidney Disease or Kidney Failure on Dialysis Who Have Inadequate Glycemic Control.
MK-3102; Placebo to MK-3102; Glipizide; Placebo to glipizide; Insulin

Diabetes Mellitus, Type 2 Clinical Trial using Metformin; Sitagliptin / Metformin; Placebo to Metformin; Placebo to Sitagliptin / Metformin

Merck Sharp & Dohme Corp. - Recruiting 10 years to 17 years.
- A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients With Type 2 Diabetes Mellitus.
Metformin; Sitagliptin / Metformin; Placebo to Metformin; Placebo to Sitagliptin / Metformin

Type 2 Diabetes Mellitus Clinical Trial using MK-0431A XR; Placebo to MK-0431A XR; Metformin XR; Placebo to metformin XR; Insulin glargine

Merck Sharp & Dohme Corp. - Recruiting 10 years to 17 years.
- A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-dose Combination Tablet of Sitagliptin and Extended-release Metformin) in Pediatric Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy.
MK-0431A XR; Placebo to MK-0431A XR; Metformin XR; Placebo to metformin XR; Insulin glargine

Diabetes Mellitus, Type 2 Clinical Trial using Linagliptin; Empagliflozin + Linagliptin; Empaglifozin placebo + Linagliptin placebo

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy..
Linagliptin; Empagliflozin + Linagliptin; Empaglifozin placebo + Linagliptin placebo

Diabetes Mellitus, Type 2 Clinical Trial using Trajenta duo

Boehringer Ingelheim - Recruiting 18 years or older.
- A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta Duo® (Linagliptin/Metformin HCl, 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1000 mg, b.i.d) in Korean Patients With Type 2 Diabetes Mellitus.
Trajenta duo

Diabetes Mellitus, Type 2 Clinical Trial using Trajenta tablet

Boehringer Ingelheim - Recruiting 19 years or older.
- A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus(SELINA Study).
Trajenta tablet

Diabetes Mellitus, Type 2, or Healthy Clinical Trial using Empagliflozin; BI 10773

Boehringer Ingelheim - Recruiting 18 years to 70 years.
- An Open-label Mechanistic Study to Examine the Effect of Oral Empagliflozin (25 mg q.d.) on Kinetics of Renal Glucose Reabsorption in Patients With Type 2 Diabetes Mellitus and Healthy Controls.
Empagliflozin; BI 10773

Diabetes Mellitus, Type 1 Clinical Trial using Empagliflozin medium placebo; Empagliflozin low placebo; Empagliflozin high placebo; Empagliflozin medium; Empagliflozin low; Empagliflozin high

Boehringer Ingelheim - Recruiting 18 years to 65 years.
- A 28-day Randomised, Placebo-controlled, Double-blind Parallel Group Phase IIa Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once Daily Oral Doses of 2.5 mg, 10 mg, and 25 mg Empagliflozin as Adjunctive to Insulin in Patients With Type 1 Diabetes Mellitus (EASE-2).
Empagliflozin medium placebo; Empagliflozin low placebo; Empagliflozin high placebo; Empagliflozin medium; Empagliflozin low; Empagliflozin high

Diabetes Mellitus, Type 2 Clinical Trial using Placebo; Linagliptin 5mg

Boehringer Ingelheim - Recruiting 18 years to 80 years.
- A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin).
Placebo; Linagliptin 5mg

Diabetes Mellitus, Type 2 Clinical Trial using OAD; Trazenta

Boehringer Ingelheim - Recruiting N/A or older.
- Post Marketing Surveillance on Long Term Drug Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus.
OAD; Trazenta

Diabetes Mellitus, Type 2 Clinical Trial using BI 10773; BI 10773 Placebo; BI 10773 / BI 1356; BI 10773 / BI 1356 Placebo

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase III, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Linagliptin 5 mg Compared to Placebo, Administered as Oral Fixed Dose Combination With Empagliflozin 10 mg or 25 mg for 24 Weeks, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks of Treatment With Empagliflozin 10 mg or 25 mg on Metformin Background Therapy.
BI 10773; BI 10773 Placebo; BI 10773 / BI 1356; BI 10773 / BI 1356 Placebo

Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Clinical Trial using Teplizumab

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Recruiting 8 years to 45 years.
- AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus.
Teplizumab

Diabetes Mellitus, Type 2 Clinical Trial using Placebo; Linagliptin

Boehringer Ingelheim - Recruiting 18 years or older.
- CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk.
Placebo; Linagliptin

Diabetes Mellitus, Type 2, or Hyperglycemia Clinical Trial using Empagliflozin low dose qd; Metformin 500 mg bid; Metformin 1000 mg bid; Empagliflozin high dose qd; Empagliflozin low dose bid; Empagliflozin high dose bid

Boehringer Ingelheim - Recruiting 18 years or older.
- A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus.
Empagliflozin low dose qd; Metformin 500 mg bid; Metformin 1000 mg bid; Empagliflozin high dose qd; Empagliflozin low dose bid; Empagliflozin high dose bid

Diabetes Mellitus, Type 2 Clinical Trial using placebo; BI1356 low dose; BI1356 high dose

Boehringer Ingelheim - Recruiting 10 years to 17 years.
- A Randomised, Double-blind, Placebo-controlled, Parallel Group Dose-finding Study of Linagliptin (1 and 5 mg Administered Orally Once Daily) Over 12 Weeks in Children and Adolescents, From 10 to 17 Years of Age, With Type 2 Diabetes Mellitus.
placebo; BI1356 low dose; BI1356 high dose

Type 1 Diabetes Mellitus Clinical Trial using Secukinumab; Placebo

Novartis - Recruiting 8 years to 35 years.
- A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus (T1D).
Secukinumab; Placebo

Exocrine Pancreatic Insufficiency in Subjects With Diabetes Melli Clinical Trial using Creon; Creon 25000 matching Placebo

Abbott - Recruiting 30 years or older.
- A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creonr on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2.
Creon; Creon 25000 matching Placebo

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using insulin degludec; insulin glargine; insulin aspart

Novo Nordisk - Recruiting 18 years or older.
- A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (BEGIN™: Switch 1).
insulin degludec; insulin glargine; insulin aspart

Essential Hypertension Complicated by Type 2 Diabetes Mellitus Clinical Trial using Azilsartan; Telmisartan

Takeda - Recruiting 20 years or older.
- A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R.
Azilsartan; Telmisartan

Hypoglycemia Clinical Trial using G-Pen Mini™ (glucagon injection)

Xeris Pharmaceuticals - Recruiting 18 years to 30 years.
- A Randomized, Phase 2a, Blinded, 3-Way Crossover Dose-Ranging Study With G-Pen Mini™ (Glucagon Injection) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Type 1 Diabetes Mellitus (T1DM).
G-Pen Mini™ (glucagon injection)

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using liraglutide; placebo

Novo Nordisk - Recruiting 18 years to 75 years.
- The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial.
liraglutide; placebo

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using semaglutide; exenatide

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAINT 3 - vs. QW GLP-1).
semaglutide; exenatide

Type 2 Diabetes Mellitus Clinical Trial using DIAMOND System

Metacure - Recruiting 21 years to 70 years.
- An Advanced Configuration (The Third Generation) of the DIAMOND System for the Treatment of T2DM Patients - A Randomized, Double Blind Study.
DIAMOND System

Type 2 Diabetes Mellitus, or Cardiovascular Disease Clinical Trial using Liraglutide; Sitagliptin

University of Leicester - Recruiting 18 years to 50 years.
- Impact of Liraglutide on Cardiac Function and Structure in Young Adults With Type 2 Diabetes: an Open-label, Randomised Active-comparator Trial.
Liraglutide; Sitagliptin

Diabetes Mellitus, Type 2, or Albuminuria Clinical Trial using Placebo; Canagliflozin, 100 mg; Canagliflozin, 300 mg

Janssen Research & Development, LLC - Recruiting 30 years or older.
- A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus.
Placebo; Canagliflozin, 100 mg; Canagliflozin, 300 mg

Diabetes Mellitus, Type 1 Clinical Trial using dietary intervention

Helsinki University - Recruiting N/A to 12 Months.
- Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity: Potential Mechanisms.
dietary intervention

Heart Failure Clinical Trial using BAY94-8862; Eplerenone; Placebo

Bayer - Recruiting 18 years or older.
- A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of BAY94-8862 in Japanese Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone Versus Eplerenone.
BAY94-8862; Eplerenone; Placebo

Type 2 Diabetes Mellitus Clinical Trial using Ertugliflozin 5 mg; Ertugliflozin 15 mg; Placebo to Ertugliflozin; Glimepiride; Placebo to Glimepiride; Basal Insulin; Metformin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy.
Ertugliflozin 5 mg; Ertugliflozin 15 mg; Placebo to Ertugliflozin; Glimepiride; Placebo to Glimepiride; Basal Insulin; Metformin

Diabetes Mellitus, Type 2 Clinical Trial using Ticagrelor 90 mg; Ticagrelor placebo

AstraZeneca - Recruiting 50 years or older.
- A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study).
Ticagrelor 90 mg; Ticagrelor placebo

Diabetes Mellitus, or Obesity Clinical Trial using Oral glucose tolerance test

National Institutes of Health Clinical Center (CC) - Recruiting 19 years to 65 years.
- Inhibition of Intestinal Glucose Absorption by the Bioflavonoid Quercetin in the Obese and in Obese Type 2 Diabetics.
Oral glucose tolerance test

Morbid Obesity, Diabetes Mellitus Type 2, Insulin Resistance, Obs Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Study of the Phenotype of Overweight and Obese Adults.

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using insulin aspart (FIAsp); insulin aspart; insulin glargine

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes.
insulin aspart (FIAsp); insulin aspart; insulin glargine

Type 1 Diabetes, or Hypoglycemia Unawareness Clinical Trial using Naltrexone

University of Minnesota - Clinical and Translational Science Institute - Recruiting 18 years to 65 years.
- Study of the Effect of Naltrexone on Cerebral Blood Flow and Hypoglycemia in Type 1 Diabetes Mellitus.
Naltrexone

Diabetes Mellitus, Type 1 Clinical Trial

Yale University - Recruiting 10 years to 37 years.
- ITN0127AI Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes (AbATE) Follow-Up Study.

Type 2 Diabetes Mellitus Clinical Trial using Lixisenatide (AVE0010); Placebo

Sanofi - Recruiting 10 years to 65 years.
- A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Paediatric (10 - 17 Years Old) and Adult Patients With Type 2 Diabetes.
Lixisenatide (AVE0010); Placebo

Type 2 Diabetes Mellitus Clinical Trial using lixisenatide AVE0010

Sanofi - Recruiting 20 years or older.
- An Open-label, Multicenter 24-Week And 52-Week Study Assessing The Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes.
lixisenatide AVE0010

Type 2 Diabetes Mellitus Clinical Trial using Lixisenatide (AVE0010); Placebo

Sanofi - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Metformin.
Lixisenatide (AVE0010); Placebo

Type 2 Diabetes Clinical Trial using Insulin glargine/lixisenatide HOE901/AVE0010; Insulin glargine HOE901; Lixisenatide AVE0010; Metformin

Sanofi - Recruiting 18 years or older.
- A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus T2DM.
Insulin glargine/lixisenatide HOE901/AVE0010; Insulin glargine HOE901; Lixisenatide AVE0010; Metformin

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using semaglutide; oral placebo

Novo Nordisk - Recruiting 18 years or older.
- Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes.
semaglutide; oral placebo

Diabetes Mellitus Type 2, or Hypertension Clinical Trial using Ginseng; Wheat Bran

St. Michael's Hospital, Toronto - Recruiting 40 years to 75 years.
- Efficacy and Safety of Combined Rg3-enriched Korean Red Ginseng (Panax Ginseng C.A. Meyer) and American Ginseng (Panax Quinquefolius) as Poly-therapy in the Management of Concomitant Hypertension in Type 2 Diabetes.
Ginseng; Wheat Bran

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using insulin degludec/insulin aspart; insulin aspart; insulin detemir

Novo Nordisk - Recruiting 1 year to 17 years.
- A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus.
insulin degludec/insulin aspart; insulin aspart; insulin detemir

Diabetes Mellitus, Type 2 Clinical Trial using PF-06291874; Placebo

Pfizer - Recruiting 18 years to 70 years.
- A Phase 1, Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Escalating Oral Doses Of PF-06291874 In Adults With Type 2 Diabetes Mellitus.
PF-06291874; Placebo

Type 2 Diabetes Mellitus, or Obesity Clinical Trial using 13C inulin; Inulin; Placebo

Maastricht University Medical Center - Recruiting 20 years to 50 years.
- SCFA Production and Their Metabolic Effects After Inulin Ingestion.
13C inulin; Inulin; Placebo

Obesity, Morbid, or Diabetes Mellitus Type 2 Clinical Trial

Merck Sharp & Dohme Corp. - Recruiting 20 years to 60 years.
- Gut Hormone Profiling in Peripheral Blood After Bariatric Surgery in Obese Patients With Type 2 Diabetes.

Long-standing Type 1 Diabetes Mellitus Clinical Trial using Beta-Air device for encapsulation of transplanted human islets

Uppsala University Hospital - Recruiting 18 years or older.
- An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus.
Beta-Air device for encapsulation of transplanted human islets

Type 2 Diabetes Mellitus Clinical Trial using Telemedical coaching; Telemedicine

West German Center of Diabetes and Health - Recruiting 25 years to 79 years.
- Diabetes Coaching Study.
Telemedical coaching; Telemedicine

Diabetic Nephropathies Clinical Trial using BAY94-8862; Placebo

Bayer - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy.
BAY94-8862; Placebo

Diabetic Nephropathies Clinical Trial using BAY94-8862; Placebo; BAY 94-8862

Bayer - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy.
BAY94-8862; Placebo; BAY 94-8862

Diabetes Mellitus, Type 2 Clinical Trial using Web-based insulin titration

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) - Recruiting 18 years to 80 years.
- Web-based Insulin Titration: Improving Diabetes Care in the Netherlands. An Efficacy Study..
Web-based insulin titration

Type 2 Diabetes Mellitus Clinical Trial using MK-3102; Glimepiride; MK-3102 Placebo; Glimepiride Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Multicenter, Double-Blind, Randomized Trial to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus For Whom Metformin is Inappropriate Due to Intolerance or Contraindication.
MK-3102; Glimepiride; MK-3102 Placebo; Glimepiride Placebo

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using semaglutide; placebo

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-na‹ve Subjects With Type 2 Diabetes.
semaglutide; placebo

Type 2 Diabetes Mellitus Clinical Trial using Ertugliflozin; Placebo

Merck Sharp & Dohme Corp. - Recruiting 40 years or older.
- Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease.
Ertugliflozin; Placebo

Diabetes Mellitus, Type 2 Clinical Trial using PF-05175157; Placebo

Pfizer - Recruiting 18 years to 65 years.
- A 6-Week Phase 2a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 As Monotherapy In Subjects With Type 2 Diabetes Mellitus.
PF-05175157; Placebo

Type 2 Diabetes Mellitus Clinical Trial using Ertugliflozin; Placebo

Merck Sharp & Dohme Corp. - Recruiting 25 years or older.
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Background Antihyperglycemic Therapy.
Ertugliflozin; Placebo

Diabetes Mellitus Clinical Trial using MK-3102; Placebo to MK-3102; Metformin

Merck Sharp & Dohme Corp. - Recruiting 18 years to 44 years.
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-3102 in ò18 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control.
MK-3102; Placebo to MK-3102; Metformin

Type 2 Diabetes Mellitus Clinical Trial using Ertugliflozin; Glimepiride; Placebo to Ertugliflozin; Placebo to Glimepiride; Metformin; Sitagliptin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin.
Ertugliflozin; Glimepiride; Placebo to Ertugliflozin; Placebo to Glimepiride; Metformin; Sitagliptin

Obesity, Insulin Resistance, Overweight, or Diabetes Mellitus, Ty Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 8 years to 25 years.
- Natural History of Type 2 Diabetes Mellitus in Children and Young Adults.

Type 2 Diabetes Mellitus Clinical Trial using Sitagliptin/metformin XR; Placebo

Merck Sharp & Dohme Corp. - Recruiting 10 years to 17 years.
- A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients With Type 2 Diabetes to Swallow MK-0431A XR Tablets.
Sitagliptin/metformin XR; Placebo

Diabetes Mellitus, Type 1 Clinical Trial using LY2605541; Insulin Glargine

Eli Lilly and Company - Recruiting 18 years to 65 years.
- Assessment of the Effects of LY2605541 on Triglyceride Metabolism, Compared to Insulin Glargine, in Patients With Type 1 Diabetes Mellitus.
LY2605541; Insulin Glargine

Diabetes Mellitus, Type 2, or Obesity Clinical Trial using Sport; Tocilizumab; Sitagliptin

University of Zurich - Recruiting 18 years to 75 years.
- A Lifestyle Intervention Study Investigating the Role of Interleukin-6 in the Beneficial Effect of Exercise on Beta-cell Function in Obese People and Patients With Type 2 Diabetes.
Sport; Tocilizumab; Sitagliptin

Diabetes Mellitus Type 2 Clinical Trial

GWT-TUD GmbH - Recruiting 18 years or older.
- Evaluation of the Impact of the CONTOURr USB Blood Glucose Monitoring System With Integrated Data Management on Glycaemic Control in Insulin-treated Diabetic Patients.

Type 2 Diabetes Mellitus, or Periodontal Disease Clinical Trial using non-surgical periodontal treatment; Supragingival biofilm control

University of Sao Paulo - Recruiting 30 years to 80 years.
- .
non-surgical periodontal treatment; Supragingival biofilm control

Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen D Clinical Trial using Acyline; Testosterone 1.62% gel; Letrozole; Placebo gel (for Testosterone 1.62% gel); Placebo pill (for Letrozole)

University of Washington - Recruiting 25 years to 55 years.
- Androgen-mediated Pathways in the Regulation of Insulin Sensitivity in Men.
Acyline; Testosterone 1.62% gel; Letrozole; Placebo gel (for Testosterone 1.62% gel); Placebo pill (for Letrozole)

Nervous System, Diabetic Kidney Disease, or Diabetes Mellitus, Ty Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Determinants of Diabetic Nephropathy in American Indians.

Diabetes Mellitus, Type 2, or Hypertension Clinical Trial using Canagliflozin; Placebo

Janssen Scientific Affairs, LLC - Recruiting 18 years to 75 years.
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Blood Pressure Reduction With Ambulatory Blood Pressure Monitoring (ABPM), Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Hypertension and Type 2 Diabetes Mellitus.
Canagliflozin; Placebo

Type-2 Diabetes Mellitus, or Ischemic Heart Disease Clinical Trial

Thebiosignals.com - Recruiting 18 years to 80 years.
- Risk Prediction in Type II Diabetics With Ischemic Heart Disease by Cardiac Autonomic Function.

Diabetes Mellitus Clinical Trial using Luyxumia versus Lantus

Profil Institut fr Stoffwechselforschung GmbH - Recruiting 18 years or older.
- A Bicentric Open-label, Randomized, Two-parallel-group Study Investigating the Impact of Combined Lantus Insulin Glargine) and Lyxumia(Lixisenatide) on Insulin Secretion and Gastric Emptying in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled on Diet and Oral Antidiabetic Medication.
Luyxumia versus Lantus

Diabetes Mellitus, Type 2 Clinical Trial using Modified paleolithic diet and exercise under observation; Modified paleolithic diet and general advice on exercise

Ume† University - Recruiting 30 years to 65 years.
- Diet and Exercise in Type 2 Diabetes - a Randomized Controlled Trial.
Modified paleolithic diet and exercise under observation; Modified paleolithic diet and general advice on exercise

Coronary Artery Disease, or Diabetes Mellitus Type 2 Clinical Trial using Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere

Mayo Clinic - Recruiting 40 years to 60 years.
- Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes: Modulation by Glucagon-Like-Peptide-1.
Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere

Diabetes Mellitus Type 1 Clinical Trial using Glucometer GM-205

GlucoVista - Recruiting 18 years to 65 years.
- .
Glucometer GM-205

Chronic Kidney Disease, or Type 2 Diabetes Mellitus Clinical Trial using AZD1722; Placebo

Ardelyx - Recruiting 18 years to 80 years.
- An Exploratory Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD1722 in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria.
AZD1722; Placebo

Type 1 Diabetes Mellitus Clinical Trial using Blood draw

City of Hope Medical Center - Recruiting 18 years or older.
- Detection of Human Beta Cell Death in T1DM by Methylation Specific PCR.
Blood draw

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using semaglutide; sitagliptin; placebo

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAINT 2 - vs. DPP-4 Inhibitor).
semaglutide; sitagliptin; placebo

Type 2 Diabetes Mellitus Clinical Trial using lixisenatide AVE0010; biguanide; TZD; alpha-GI; glinide

Sanofi - Recruiting 20 years or older.
- An Open-Label, Multicenter 52-Week Study Assessing the Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes.
lixisenatide AVE0010; biguanide; TZD; alpha-GI; glinide

Islet Transplantation in Diabetes Mellitus Type 1, Clinical Trial using Reparixin; Placebo

Domp‚ s.p.a. - Recruiting 18 years to 70 years.
- A Phase 3, Multicenter, Randomized, Double-blind, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Transplantation.
Reparixin; Placebo

Diabetes Mellitus, Type 2 Clinical Trial

Ohio State University - Recruiting 40 years to 60 years.
- Leukocyte Dysfunction in Diabetic Patients..

Type 2 Diabetes Clinical Trial using fotonovela

University of California, San Francisco - Recruiting 18 years or older.
- Utility of a Diabetes Themed Fotonovela to Encourage Glycemic Control: a Culturally Appropriate Tool for Education in Latinos.
fotonovela

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using insulin aspart (faster acting insulin aspart); insulin aspart

Novo Nordisk - Recruiting 18 years to 64 years.
- A Trial Investigating the Pharmacodynamic Response of FIAsp in Subjects With Type 1 Diabetes.
insulin aspart (faster acting insulin aspart); insulin aspart

Heart Failure Clinical Trial using BAY94-8862; Placebo; Inspra (eplerenone)

Bayer - Recruiting 18 years or older.
- A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone.
BAY94-8862; Placebo; Inspra (eplerenone)

Diabetes Mellitus, Type 2 Clinical Trial using INSULIN GLARGINE (HOE901); INSULIN GLULISINE (HMR1964)

Sanofi - Recruiting 21 years or older.
- A Comparative Study to Evaluate the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 DM Patients Uncontrolled With a Basal Insulin or Premix Once a Day.
INSULIN GLARGINE (HOE901); INSULIN GLULISINE (HMR1964)

Type 2 Diabetes Mellitus Clinical Trial using Dulaglutide; Glimepiride; Placebo

Eli Lilly and Company - Recruiting 18 years or older.
- The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus.
Dulaglutide; Glimepiride; Placebo

Overweight, Obesity, Type 2 Diabetes Mellitus Clinical Trial using AZP-531

Aliz‚ Pharma - Recruiting 18 years to 50 years.
- A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus.
AZP-531

Type 2 Diabetes Mellitus Clinical Trial using Insulin Lispro Mix25; Insulin Lispro Mix50

Eli Lilly and Company - Recruiting 18 years or older.
- Comparison Between Low Mixed Insulin and Mid Mixed Insulin AS Starter Insulin For Patients With TYpe 2 Diabetes Mellitus (CLASSIFY Study).
Insulin Lispro Mix25; Insulin Lispro Mix50

Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, Clinical Trial using Imatinib Mesylate; Placebo (For imatinib mesylate)

University of California, San Francisco - Recruiting 18 years to 45 years.
- Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-Onset Type 1 Diabetes Mellitus.
Imatinib Mesylate; Placebo (For imatinib mesylate)

Type 1 Diabetes Mellitus Clinical Trial

UMC Utrecht - Recruiting 18 years or older.
- Ovarian Ageing in Type 1 Diabetes Mellitus: the Role of Vascular Factors.

Type 2 Diabetes Mellitus Clinical Trial using LY3053102; Exenatide extended release; Placebo

Eli Lilly and Company - Recruiting 21 years or older.
- Safety, Tolerability, Pharmacokinetics, and Efficacy of LY3053102 With 12 Weeks of Treatment in Patients With Type 2 Diabetes Mellitus.
LY3053102; Exenatide extended release; Placebo

Type 2 Diabetes Mellitus Clinical Trial using LY2605541; Insulin Glargine

Eli Lilly and Company - Recruiting 20 years or older.
- A Phase 3, Open Label, Randomized, Parallel, 26 Week Treatment Study Comparing LY2605541 With Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti Hyperglycemia Medications in Asian Insulin Na‹ve Patients With Type 2 Diabetes Mellitus.
LY2605541; Insulin Glargine

Type-2 Diabetes Mellitus, or Coronary Artery Disease Clinical Trial using Ticagrelor + Aspirin; Clopidogrel + Aspirin

Mount Sinai School of Medicine - Recruiting 18 years to 75 years.
- Comparative Study of the Antithrombotic Effects of Ticagrelor and Clopidogrel in Type 2 Diabetic Patients.
Ticagrelor + Aspirin; Clopidogrel + Aspirin

Type 2 Diabetes Mellitus, or Iron Deficiency Clinical Trial using ferric carboxymaltose; NaCl (0,9%)

GWT-TUD GmbH - Recruiting 18 years or older.
- Intravenous Ferric Carboxymaltose for Improvement of Metabolic Parameters and Vascular Function in T2DM-patients With Iron Deficiency.
ferric carboxymaltose; NaCl (0,9%)

Diabetes Mellitus, or Type 2 Diabetes Clinical Trial using Sitagliptin; Metformin; Placebo to sitagliptin; Placebo to metformin

Merck Sharp & Dohme Corp. - Recruiting 10 years to 17 years.
- A Phase III, Multicenter, Double-Blind, Randomized, Placebo and Metformin-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control.
Sitagliptin; Metformin; Placebo to sitagliptin; Placebo to metformin

Type 2 Diabetes Mellitus Clinical Trial using MK-3012; Matching placebo to MK-3012; Glimepiride; Matching placebo to glimepiride; Insulin glargine; Metformin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy.
MK-3012; Matching placebo to MK-3012; Glimepiride; Matching placebo to glimepiride; Insulin glargine; Metformin

Type 2 Diabetes Mellitus Clinical Trial using Low Glycemic Index (LGI) intervention arm; Standard Diet Intervention

National University Hospital, Singapore - Recruiting 45 years to 64 years.
- Nutrition Studies and Dietary Intervention in Individuals With Type 2 Diabetes Mellitus of Chinese, Malay and Indian Ethnicity.
Low Glycemic Index (LGI) intervention arm; Standard Diet Intervention

Type 1 Diabetes Mellitus Clinical Trial using LY2605541; Insulin Glargine

Eli Lilly and Company - Recruiting 18 years to 60 years.
- Evaluation of the Effects of LY2605541 on Respiratory Quotient During Sleep and Response to Hyperinsulinemia Compared With That of Insulin Glargine in Patients With Type 1 Diabetes Mellitus.
LY2605541; Insulin Glargine

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using insulin aspart (FIAsp); insulin aspart

Novo Nordisk - Recruiting 6 years to 64 years.
- A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes.
insulin aspart (FIAsp); insulin aspart

Diabetic Nephropathy Clinical Trial using colchicine 0.5mg/d; placebo 0.5mg/d

Chongqing Medical University - Recruiting 30 years to 70 years.
- Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study.
colchicine 0.5mg/d; placebo 0.5mg/d

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using liraglutide; metformin; sulfonylurea

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes.
liraglutide; metformin; sulfonylurea

Diabetes, Diabetes Mellitus, Type 2, or Healthy Clinical Trial using semaglutide

Novo Nordisk - Recruiting 18 years to 85 years.
- Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function.
semaglutide

Diabetes Mellitus, Type 1 Clinical Trial using Intranasal Glucagon; Glucagon

T1D Exchange Clinic Network Coordinating Center - Recruiting 4 years to 16 years.
- Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes.
Intranasal Glucagon; Glucagon

Type 2 Diabetes Mellitus Clinical Trial using LAF237 50 mg; Placebo

Novartis - Recruiting 20 years to 74 years.
- A 12-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Equa (Vildagliptin) 50 mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus.
LAF237 50 mg; Placebo

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using insulin aspart (FIAsp); basal insulin

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes.
insulin aspart (FIAsp); basal insulin

Diabetes Mellitus, Type 1, or Diabetes Mellitus, Type 2 Clinical Trial using Intranasal Glucagon; Glucagon

T1D Exchange Clinic Network Coordinating Center - Recruiting 18 years to 64 years.
- Efficacy and Safety of Intranasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes.
Intranasal Glucagon; Glucagon

Type 2 Diabetes Mellitus Clinical Trial using Ursodiol

Mayo Clinic - Recruiting 18 years to 70 years.
- Effect of Delayed-Release Ursodeoxycholic Acid on Insulin Sensitivity, Gastric Emptying and Body Weight in Overweight or Obese Patients With Type 2 Diabetes on Metformin Treatment.
Ursodiol

Diabetes Mellitus, Type 2 Clinical Trial using PL2200 Aspirin Capsules; Enteric-coated aspirin caplets

PLx Pharma - Recruiting 21 years to 79 years.
- Reliable Inhibition of Thrombocyte Activity: Comparison of PL2200 Aspirin Capsules, 325 mg and Enteric-Coated Aspirin (RITE Study).
PL2200 Aspirin Capsules; Enteric-coated aspirin caplets

Diabetes Mellitus, Type 2 Clinical Trial using Placebo - Capsule; LY3108743 - Capsule; Placebo - Solution; LY3108743 - Solution

Eli Lilly and Company - Recruiting 21 years to 65 years.
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of LY3108743 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.
Placebo - Capsule; LY3108743 - Capsule; Placebo - Solution; LY3108743 - Solution

Type 2 Diabetes Mellitus (T2DM) Clinical Trial using PE0139 Injection; Placebo

PhaseBio Pharmaceuticals Inc. - Recruiting 18 years to 65 years.
- Phase 1 Multicenter, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus.
PE0139 Injection; Placebo

Diabetes Mellitus Type 1 Clinical Trial using BioChaperone insulin lispro; Humalogr

Adocia - Recruiting 18 years to 64 years.
- A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalogr) in Subjects With Type 1 Diabetes.
BioChaperone insulin lispro; Humalogr

Overweight, or Diabetes Mellitus Type 2 in Obese Clinical Trial using P11187; Placebo

Piramal Enterprises Limited - Recruiting 18 years to 70 years.
- A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P11187.
P11187; Placebo

Type 2 Diabetes Mellitus With Diabetic Nephropathy Clinical Trial using GKT137831; Placebo

Genkyotex Innovation SAS - Recruiting 18 years to 80 years.
- A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients With Type 2 Diabetes and Albuminuria.
GKT137831; Placebo

Diabetes Mellitus, Type 2 Clinical Trial using INSULIN GLARGINE; Metformin; DPP-4 inhibitor; Sulphonylurea

Sanofi - Recruiting 20 years or older.
- Efficacy and Safety of TrEating Type 2 Diabetic Patients With Inadequate Response to Metformin and DPP-4 Inhibitors by Adding Basal Insulin Therapy (Insulin Glargine).
INSULIN GLARGINE; Metformin; DPP-4 inhibitor; Sulphonylurea

Diabetes, Diabetes Mellitus, Type 2, or Healthy Clinical Trial using semaglutide; placebo; metformin; warfarin

Novo Nordisk - Recruiting 18 years to 55 years.
- An Open-label, One-sequence Cross Over, Single Centre Trial, Investigating the Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects.
semaglutide; placebo; metformin; warfarin

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using insulin degludec/liraglutide; insulin glargine

Novo Nordisk - Recruiting 18 years or older.
- A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUALTM V - Basal Insulin Switch).
insulin degludec/liraglutide; insulin glargine

Diabetes Mellitus, Type 2 Clinical Trial using glimepiride; glargine and metformin

Chongqing Medical University - Recruiting 35 years to 70 years.
- Efficacy/Safety Study of Adding Glimepiride to Type 2 Diabetes Patients With Inadequate Glycemic Control Based on Combination With Metformin And Basal Insulin.
glimepiride; glargine and metformin

Diabetes Mellitus, Insulin-Dependent, or Type 1 Clinical Trial using Oshadi Icp

Oshadi Drug Administration - Recruiting 21 years or older.
- A Single Center, Multiple-dose, Non-randomized, Dose Adjustment, Open-Label Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Tolerability of Oshadi Icp in Patients With Type 1 Diabetes Mellitus -A Phase II Clinical Study.
Oshadi Icp

Diabetes, Diabetes Mellitus, Type 2, or Healthy Clinical Trial using semaglutide

Novo Nordisk - Recruiting 18 years to 85 years.
- Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide (NNC0113-0217) in Subjects With Mild, Moderate and Severe Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.
semaglutide

Diabetes Mellitus Clinical Trial using Microprobe glucose sensor

Imperial College London - Recruiting 18 years to 75 years.
- Clinical Assessment of a Novel Microprobe Array Continuous Glucose Monitor for Type 1 Diabetes.
Microprobe glucose sensor

Diabetes Mellitus Clinical Trial using MK-8521; Liraglutide; Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years to 69 years.
- A Phase Ib, Multicenter, Placebo and Active- Comparator-Controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Subjects With Type 2 Diabetes Mellitus.
MK-8521; Liraglutide; Placebo

Diabetes Mellitus, Type 2, or Healthy Volunteers Clinical Trial using Dulaglutide; Placebo

Eli Lilly and Company - Recruiting 18 years to 75 years.
- Pharmacokinetics of a Single Dulaglutide Dose in Healthy Chinese Subjects and of Multiple Dulaglutide Doses in Chinese Patients With T2DM.
Dulaglutide; Placebo

Diabetes, or Diabetes Mellitus, Type 1 Clinical Trial using BioChaperoner Combo; Humalogr Mix25

Adocia - Recruiting 18 years to 64 years.
- Phase 1 Study to Assess the Efficacy and Safety of BioChaperoner Combo and Humalogr Mix 25 in Subjects With Type 1 Diabetes.
BioChaperoner Combo; Humalogr Mix25

Diabetic Neuropathy, or Cognitive Impairment Clinical Trial using Tocotrienol; Placebo

University of Science Malaysia - Recruiting 20 years or older.
- A Clinical Study on the Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus.
Tocotrienol; Placebo

Diabetes, or Diabetes Mellitus, Type 2 Clinical Trial using liraglutide; lixisenatide

Novo Nordisk - Recruiting 18 years or older.
- Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes.
liraglutide; lixisenatide

Diabetes Mellitus Type 2, or Obesity Clinical Trial using Behavioural change programme

Norwegian University of Science and Technology - Recruiting 18 years to 65 years.
- The VEND RISK-study. Preventing Diabetes Type 2 in Overweight Persons in the V‘rnes Region, Central-Norway..
Behavioural change programme

Type 2 Diabetes Mellitus, or Cardiovascular Disease Clinical Trial using Saxagliptin

Duke University - Recruiting 45 years to 75 years.
- Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Saxagliptin

Type 2 Diabetes Mellitus, or Nephropathy Clinical Trial using Valsartan; Placebo; Probucol

Guangdong General Hospital - Recruiting 30 years to 70 years.
- A Prospective Randomized, Controlled, Open-labeled Trial of Probucol Combined With Valsartan in Patients With Diabetes Nephropathy.
Valsartan; Placebo; Probucol

Celiac Disease, or Diabetes Mellitus, Type 1 Clinical Trial using Gluten Free Diet

The Hospital for Sick Children - Recruiting 8 years to 35 years.
- A Randomized Controlled Trial to Evaluate the Efficacy and Safety of a Gluten-Free Diet in Patients With Asymptomatic Celiac Disease and Type 1 Diabetes, Celiac Disease and Diabetes - Dietary Intervention and Evaluation Trial (CD-DIET).
Gluten Free Diet

Diabetes Mellitus Type 1, or Retinal Branch Vein Occlusion Clinical Trial using COX inhibitor; L-NG-monomethyl arginine citrate; COX inhibitor + L-NG-monomethyl arginine citrate

University of Aarhus - Recruiting 20 years to 55 years.
- Diameter Changes of Retinal Vessels During Hypoxia.
COX inhibitor; L-NG-monomethyl arginine citrate; COX inhibitor + L-NG-monomethyl arginine citrate

Diabetes Mellitus Type 2 in Obese, or Obesity Clinical Trial

Mayo Clinic - Recruiting 21 years to 55 years.
- Epigenetics and the Origin of Muscle Insulin Resistance in Humans.

Diabetes, or Hypothyroidism Clinical Trial using Euthyrox (levothyroxine)

Maastricht University Medical Center - Recruiting 40 years to 65 years.
- Effects of Thyroid Hormone Treatment on Mitochondrial Function, Ectopic Fat Accumulation, Insulin Sensitivity and Brown Adipose Tissue in Type 2 Diabetes Mellitus.
Euthyrox (levothyroxine)

Critical Lower Limb Ischemia, or Type-2 Diabetes Mellitus Clinical Trial using Group A: Intramuscular; Group B: Intraarterial; Group C: Intravenous; Group D: Surgical endovascular treatment with maximum medicamentous treatment

University Hospital Ostrava - Recruiting 18 years or older.
- Randomised Clinical Study of Safety and Efficacy of Autologous Bone Marrow Aspirate Concentrate (BMAC) for No-option_critical Limb Ischemia in Type-II Diabetes Mellitus Patients. (DIALEG).
Group A: Intramuscular; Group B: Intraarterial; Group C: Intravenous; Group D: Surgical endovascular treatment with maximum medicamentous treatment

Type 1 Diabetes Mellitus Clinical Trial using iBOLUSED

University of Virginia - Recruiting 21 years to 65 years.
- Evaluation of a Simulation-Based Educational Tool for Personalized Feedback in Insulin Therapy Management.
iBOLUSED

Diabetes Mellitus Type II Clinical Trial using NONE intervention

Ziv Hospital - Recruiting 35 years or older.
- Predictors of Future Type 2 Diabetes Mellitus in Circassians Minority in Israel.
NONE intervention

Type II Diabetes Mellitus, or Obesity Clinical Trial using PolyGlycopleXr - PGXr; Rice Flour (placebo)

InovoBiologic Inc. - Recruiting 18 years to 75 years.
- A Randomized, Double Blind, Placebo Controlled Trial Evaluating the Effects of a Highly Viscous Non-starch Polysaccharide (PolyGlycopleXr - PGXr), on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics Enrolled in a Medically Supervised Weight Management Program..
PolyGlycopleXr - PGXr; Rice Flour (placebo)

Type 1 Diabetes Mellitus Clinical Trial using Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM); Multiple daily insulin injections (MDI)

Steno Diabetes Center - Recruiting 18 years to 75 years.
- The Effect of Sensor-Augmented Continuous Subcutaneous Insulin Infusion Compared to Multiple Daily Insulin Injections in Prevention of Increasing Urinary Albumin Excretion Rate in Type 1 Diabetes Mellitus.
Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM); Multiple daily insulin injections (MDI)

Diabetes Mellitus, or Diabetic Retinopathy Clinical Trial using Insulin pump; Multiple daily insulin injections; Bariatric surgery; Medical therapy for type 2 diabetes

Glostrup University Hospital, Copenhagen - Recruiting 18 years or older.
- Retinal Adaptation to Intensified Insulin Therapy and Bariatric Surgery in Patients With Diabetes.
Insulin pump; Multiple daily insulin injections; Bariatric surgery; Medical therapy for type 2 diabetes

Diabetes Mellitus, Type 2, Metabolic Syndrome X, or Mild Cognitiv Clinical Trial

Maastricht University Medical Center - Recruiting 40 years to 75 years.
- Functional MRI Biomarkers of Cognitive Decrements in Diabetes.

Type 2 Diabetes Clinical Trial using Cholecalciferol

Florida International University - Recruiting 30 years to 70 years.
- The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors Among Hispanics and African Americans With Type 2 Diabetes.
Cholecalciferol

Vitamin D Deficiency, Type 2 Diabetes Mellitus, or Cardiovascular Clinical Trial using Vitamin D3; Calcium carbonate

Washington University School of Medicine - Recruiting 50 years to 70 years.
- Vitamin D and Early Markers of Cardiovascular Disease in African Americans.
Vitamin D3; Calcium carbonate

Obesity, Morbid, Diabetes Mellitus, Type 2, or Gastric Bypass Clinical Trial

CPL Associates - Recruiting 18 years to 95 years.
- Comparison Of Endotoxin Concentration And Intestinal Microbiologic Flora Before And After Roux-En-Y Gastric Bypass Or Gastric Banding Surgery In Morbidly Obese Patients With Type 2 Diabetes Mellitus.

Type 2 Diabetes Mellitus, or Hypercholesterolemia Clinical Trial using Atorvastatin; Placebo

University of Roma La Sapienza - Recruiting 18 years to 75 years.
- Effects on Oxidative Stress, Coagulation, Platelet Activation and Inflammatory Indexes of Atorvastatin and/or Aspirin Treatment in Patients at High Risk of Vascular Events.
Atorvastatin; Placebo

Type 1 Diabetes Mellitus Clinical Trial using Lisofylline

Eastern Virginia Medical School - Recruiting 18 years to 45 years.
- A Safety, Tolerability and Bioavailability Study of Lisofylline After Continuous Subcutaneous (12 mg/kg) and Intravenous (9 mg/kg) Administration in Subjects With Type 1 Diabetes Mellitus.
Lisofylline

Type 2 Diabetes Mellitus Clinical Trial

Universita di Verona - Recruiting 18 years to 75 years.
- The Verona Newly Diagnosed Type 2 Diabetes Study. Construction of a Biobank of Diabetes Related Genotypes and Phenotypes.

Blood Pressure Clinical Trial using DASH diet plus exercise; ADA diet

Hospital de Clinicas de Porto Alegre - Recruiting 30 years to 90 years.
- Lifestyle Changes in Patients With Type 2 DM and Hypertension: DASH Diet and Exercise Effects.
DASH diet plus exercise; ADA diet

Type 2 Diabetes Mellitus Clinical Trial using Pistachios; control diet

Institut Investigacio Sanitaria Pere Virgili - Recruiting 25 years to 65 years.
- Effect of Pistachio Intake on Insulin Resistance and Type 2 Diabetes Mellitus.
Pistachios; control diet

Type 2 Diabetes Mellitus, or Weight Gain Clinical Trial using Sensewear Bodymedia armband

Radboud University - Recruiting 18 years to 85 years.
- Determinants of Insulin-induced Weight Gain in Type 2 Diabetes Mellitus.
Sensewear Bodymedia armband

Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, or Metaboli Clinical Trial

University of California, Irvine - Recruiting 40 years to 65 years.
- Mitochondria and Metabolic Syndrome in a Southern California Chinese Cohort.

Pregnancy Complications Clinical Trial using Metformin; Insulin (NPH and Regular)

The University of Texas Health Science Center, Houston - Recruiting 18 years to 52 years.
- A Randomized, Controlled Trial of Metformin Versus Insulin in Women With Type 2 Diabetes Mellitus During Pregnancy in a Population With Severe Health Disparities.
Metformin; Insulin (NPH and Regular)

Type 1 Diabetes Mellitus Clinical Trial using IN-105; Insulin Lispro Injection

Biocon Limited - Recruiting 18 years to 45 years.
- An OpenLabel, Multicenter, Non-randomized, ActiveControlled, SingleDose Escalation, Study to Evaluate the Pharmacodynamics,Pharmacokinetics,Safety, and Tolerability of IN-105 Under Fed Conditions In Patients With Type 1 Diabetes Mellitus.
IN-105; Insulin Lispro Injection

Type 2 Diabetes Clinical Trial using Gliclazide MR and Insulin Glargine Injection; Biosynthetic Human Insulin Injection

Servier (Tianjin) Pharmaceutical Co. LTD. - Recruiting 35 years to 65 years.
- Phase 4 Study of Comparison of Combination Therapy of Gliclazide MR and Basal Insulin With Pre-mix Insulin Monotherapy for the Patients With Type 2 Diabetes Mellitus.
Gliclazide MR and Insulin Glargine Injection; Biosynthetic Human Insulin Injection

Diabetes Mellitus, Type 2, or Heart Failure, Diastolic Clinical Trial using Exenatide

National Heart, Lung, and Blood Institute (NHLBI) - Recruiting 30 years or older.
- Treatment With Glucagon-Like Peptide-1 Receptor, Exenatide, in Patients With Diabetes and Heart Failure With Normal Left Ventricular Ejection Fraction.
Exenatide

Type 2 Diabetes Mellitus, or Obesity Clinical Trial using Insulatard; Detemir

University of Surrey - Recruiting 18 years or older.
- A 24-Week, National, Single-Centre, Open-Labelled, Randomised, Parallel-Group Trial Comparing Energy Expenditure With Insulin Detemir Versus NPH Insulin Using a Basal-Bolus Regimen With Insulin Aspart as the Mealtime Insulin in Subjects With Type 2 Diabetes.
Insulatard; Detemir

Type 2 Diabetes Mellitus, or Obesity Clinical Trial using Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate

Glostrup University Hospital, Copenhagen - Recruiting 18 years or older.
- Incretin Physiology and Beta-Cell Function Before and After Remission of Type 2 Diabetes - Effects of Long-Term Weight Loss Following Laparoscopic Adjustable Gastric Banding.
Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate

Diabetes Mellitus, Type 2 Clinical Trial using Rosiglitazone; dietary recommendation for weight maintenance

Stanford University - Recruiting 20 years to 75 years.
- Rosiglitazone-Induced Weight Gain.
Rosiglitazone; dietary recommendation for weight maintenance

Type 2 Diabetes Mellitus, or Hypertension Clinical Trial using Intensive therapy Valsartan,Fluvastatin

Kitasato University - Recruiting 20 years or older.
- Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension.
Intensive therapy Valsartan,Fluvastatin

Diabetes Mellitus, Type 2 Clinical Trial using Benfotiamine; Placebo

Ruhr University of Bochum - Recruiting 35 years to 70 years.
- Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System.
Benfotiamine; Placebo

Diabetes Mellitus Type 2 Clinical Trial

Assaf-Harofeh Medical Center - Recruiting 40 years to 90 years.
- Angiotensin Converting Enzyme Inhibitors & Angiotensin Receptor Blocker in the Treatment of Type 2 Diabetic Patients Adverse Drug Effects and Drug Interactions- a Survey in an Internal Medicine Department..

Diabetes Mellitus, Type 2 Clinical Trial using dual-action insulin analog

Jikei University School of Medicine - Recruiting 20 years to 80 years.
- .
dual-action insulin analog